Recent Postings to generic-tadalafil.info

Worst Pills, Best Pills Newsletter Articles

  View the entire August 2018 issue in PDF format

  View the entire July 2018 issue in PDF format

  View the entire June 2018 issue in PDF format

  • Preventing Heat-Induced Death and Illness
    (June 2018)
    This article lists practical steps to take to avoid death, hospitalization or other medical problems caused by heat stress. It also identifies over 100 drugs that can impair your response to heat and thereby increase your risk of heat-induced illness and death.
  • FDA's "Breakthrough Therapies" Designation Often Misleading
    (June 2018)
    In his editor’s column, Dr. Michael Carome discusses an analysis by researchers at Harvard University that suggests that patients and doctors are being misled about the benefits of drugs approved under the FDA’s “breakthrough therapies” pathway.
  • Antibiotic Clarithromycin May Increase Risk of Death, FDA Warns
    (June 2018)
    Clarithromycin is an oral antibiotic that is commonly used to treat a wide range of bacterial infections. Learn why patients with heart disease should avoid this antibiotic unless no other suitable antibiotic is available.
  • Do Not Use the New Oral Blood Thinner Apixaban (ELIQUIS)
    (June 2018)
    Apixaban is a new oral anticoagulant (blood thinner) that was first approved by the FDA in 2012 for decreasing the risk of blood clots in certain patients. Find out why older anticoagulant drugs, such as warfarin (COUMADIN, JANTOVEN), are a better choice.
  • Topical Clobetasol Propionate: Only Use to Treat Severe Skin Disorders
    (June 2018)
    All but one of the clobetasol propionate products are classified as super-high potency topical corticosteroids. They are approximately 1,000 times more potent than over-the-counter 1-percent hydrocortisone. This article offers advice on how to use these products safely.

Additional Information from Public Citizen

  • (July 1, 2018)
    Public Citizen petitioned the Food and Drug Administration (FDA) to ban the sale of the widely prescribed gout drug febuxostat (sold under the brand name Uloric) because use of the drug increases the risk of death compared with alternative therapies and there exist other effective medications that have been approved by the FDA for treatment of gout that have a lower risk of death.
  • (July 1, 2018)
    In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Public Citizen urged the committee to recommend that the FDA reject new drug application submitted by Pain Therapeutics for oxycodone extended-release capsules for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
  • (May 25, 2018)
    The Food and Drug Administration (FDA) agreed with Public Citizen that over-the-counter oral health care products containing benzocaine should never be used in infants under any circumstances, even with the advice and supervision of a health care professional, because of the risk of methemoglobinemia, a life-threatening blood disorder that impairs the body’s ability to use oxygen.
  • (May 23, 2018)
    The FDA’s action today to protect infants and children from exposure to over-the-counter oral health products containing benzocaine, which can cause methemoglobinemia, a life-threatening blood disorder that impairs the body’s ability to use oxygen, comes too late for some infants and children.
  • (May 22, 2018)
    In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Public Citizen urged the committee to recommend that the FDA reject INSYS Development Company’s new drug application for buprenorphine sublingual spray for the treatment of moderate-to-severe acute pain where the use of an opioid analgesic is appropriate because the risks of the drug outweigh the benefits.